Cargando…
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
The rapidly emerging field of immunotherapy and the development of novel immunologic agents that have been approved in melanoma and successfully studied in lung cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical trial analysis beyond conventional survival e...
Autor principal: | Slovin, Susan F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918229/ https://www.ncbi.nlm.nih.gov/pubmed/27471695 http://dx.doi.org/10.2147/ITT.S30821 |
Ejemplares similares
-
Immunotherapy in metastatic prostate cancer
por: Slovin, Susan F.
Publicado: (2016) -
Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012) -
Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010) -
IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014) -
Is more involvement needed in the clinical trial design & endpoints?
por: Vroom, Elizabeth
Publicado: (2012)